Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Jul 29, 2025

SELL
$11.02 - $16.09 $58,406 - $85,277
-5,300 Reduced 29.12%
12,900 $180,000
Q1 2025

Jul 16, 2025

BUY
$13.48 - $20.91 $245,336 - $380,562
18,200 New
18,200 $245,000

Others Institutions Holding VRDN

About Viridian Therapeutics, Inc.\DE


  • Ticker VRDN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,888,900
  • Market Cap $1.15B
  • Description
  • Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...
More about VRDN
Track This Portfolio

Track Virginia Retirement Systems Et Al Portfolio

Follow Virginia Retirement Systems Et Al and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virginia Retirement Systems Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Virginia Retirement Systems Et Al with notifications on news.